Polaryx Therapeutics, Inc., was originally incorporated in Wyoming on August 22, 2014. On October 24, 2025, the Company completed the re-registration process and became a Nevada corporation. Polaryx is a clinical-stage biotechnology company dedicated to discovering, developing and commercializing innovative therapies for rare childhood lysosomal storage diseases (LSDs). The Company employs a multimodal therapeutic approach, combined with small molecule drug therapy and gene therapy, aimed at addressing the genetic causes and downstream effects of these diseases. Its leading drug candidate, PLX-200, targets a variety of LSDs and has entered clinical trials. Polaryx's drug development strategy is centered on providing safe, effective, patient-centered treatment options to meet the significant unmet needs of these diseases.
